Should gene therapy be used for AMD? new study asks patients
NCT ID NCT07004361
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study interviews 30 patients with wet age-related macular degeneration to understand their views on gene therapy. Researchers want to know if the benefits outweigh the risks of this irreversible treatment, and how patients make decisions about complex therapies. The goal is not to test a treatment, but to gather patient perspectives on ethical issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXUDATIVE AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Nantes - Ophthalmology Department
RECRUITINGNantes, Nantes, 44000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye drug cut injection frequency for AMD patients?
- Scientists probe eye fluid to uncover why some macular degeneration patients Don't get better
- Can a stronger eylea dose dry up wet AMD faster?
- Fewer eye needles? Higher-Dose aflibercept shows promise for wet AMD
- Eye fluid study sheds light on AMD treatment effects
- Smartphone app could help wet AMD patients space out eye injections